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A retrospective database study of oral corticosteroid
and bisphosphonate prescribing patterns in England
Christos V. Chalitsios 1✉, Dominick E. Shaw 1 and Tricia M. McKeever2
Exposure to oral corticosteroids (OCS) is associated with an increased risk of osteoporosis and fragility fractures. Guidelines suggest
bisphosphonate (BP) therapy as the ﬁrst-line treatment of glucocorticoid-induced osteoporosis (GIOP). This population study used
publicly available data, including prescription annual cost analysis and monthly practice-level data. Our aim was to examine the
prescribing of OCS and BP at practice level and investigate reasons for variation using a mixed-effect negative binomial regression
analysis. There was a rise in OCS and BP prescriptions of 55% and 1200% from 1998 to 2018, respectively. Of the 6586 included
practices, the median (IQR) of OCS and BP prescriptions were 120.8 (84.8–160.4) and 107.7 (73.8–147.4) per 1000 patients,
respectively. Asthma and chronic obstructive pulmonary disease (COPD) were signiﬁcantly associated with OCS use (p < 0.0001), but
only COPD was associated with BP use (p < 0.0001). Higher OCS prescribing rates were associated with higher BP prescribing rates
(5th to 1st quintile—IRR= 1.99; 95% CI: 1.88–2.10). Practice list size, deprivation and advanced age were all associated with both
drugs (p < 0.0001). In conclusion, although OCS use is positively associated with BP prescription, variation among practices and
CCGs exists. The variation in prescribing suggests there is still a need to improve GIOP prevention.
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INTRODUCTION
Oral corticosteroids (OCS) (glucocorticoids) are used to treat
chronic conditions including autoimmune,1 and respiratory
diseases.2,3 Asthma and COPD are two of the most common
indications for prolonged OCS use (more than 90 days).4 Both
short-term (5−90 days) and prolonged exposure to OCS can lead
to deleterious effects5,6 including bone loss resulting in osteo-
porosis and fragility fracture.7 Bone loss is substantial and rapid
during the ﬁrst months of the OCS treatment.8 Patients with
severe asthma exposed to prednisolone 5mg per day are more
likely to be diagnosed with osteoporosis (OR= 6.5) and have a
fracture (OR= 1.5) compared to those without asthma.9 After OCS
initiation, spine fracture risk increases by 55% with exposure at
doses as low as prednisone 2.5 mg per day, whereas hip fracture
risk goes up by 50% among patients exposed to 2.5–7.5 mg
per day.10,11
Fragility fractures are also associated with substantially
increased healthcare costs, morbidity, and mortality,12,13 and
guidelines suggest all patients exposed to any dose of OCS for
more than 3 months should be considered for BP therapy to
prevent glucocorticoid-induced osteoporosis (GIOP).14,15 The
bisphosphonate class is effective in reducing bone loss and
fragility fracture risk.16,17 Despite this, only a minority of patients
with increased fragility fracture risk receive appropriate ther-
apy.18,19 There are no speciﬁc guidelines for GIOP in asthma or
COPD and the size of the potential problem is not well
established.
We are unaware of any published U.K. research investigating
the trends in OCS and anti-GIOP therapy (BP) prescribing. Our aim
was to comprehensively assess OCS and BP prescribing patterns,
at practice level, using primary care data from England and to
investigate factors associated with their prescribing, in order to
gain a better understanding of prescribing enabling us to reduce
prescribing variation and optimise GIOP prevention.
RESULTS
Practice characteristics
In our analysis, we included 195 Clinical Commissioning Groups
(CCGs) containing 6586 practices after the exclusion of 507. In
2018, the median (IQR) OCS and BP prescriptions per 1000
patients was 120.8 (84.8–160.4) and 107.7 (73.8–147.4), respec-
tively. The characteristics of practices are summarised in Table 1.
Long-term patterns and ratio between OCS and BP prescriptions
Prednisolone was the most frequently prescribed OCS. There was
a steady increase in OCS prescriptions over time (Fig. 1a). In 1998,
there were 95 OCS prescriptions per 1000 population increasing to
140 in 2018 (55% rise). The cost of OCS was £250 per 1000
population until 2006, with a noticeable increase up to just less
than £2000 the following years (Supplementary Fig. 1).
There was an increase in bisphosphonate prescribing rates over
time (Fig. 1b). In 1998, there were 10 BP prescriptions per 1000
population, while the total prescriptions reached 120 in 2018
(1200% increase). The most prescribed bisphosphonate was
alendronic acid. BP cost peaked at £3200 per 1000 population in
2005; however, there was a reduction to £101 by 2018
(Supplementary Fig. 1).
There were 0.99 OCS prescriptions per 1 BP item in 2015;
however, this relationship changed slightly to 1.16 by 2018
(Table 2).
Variations among practices and CCGs for OCS and BP items
In 2018, there was a signiﬁcant variation between OCS (m= 129.6,
SD= 38.9) and BP (m= 118.5, SD= 34.2) prescription per 1000
patients; t= 6.27, p < 0.0001. OCS prescription varied between 48
and 239 and BP ranged from 38 to 207 prescriptions per 1000
patients across CCGs. Sixty out of 195 CCGs prescribed less OCS
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than BP items, and 135 more OCS than BP items per 1000 patients
(Fig. 2).
Factors associated with OCS and BP prescribing
We found that OCS prescriptions were associated with the factors
listed in Table 3 apart from the QOF score and percentage of
patients with a long-term health disease. Asthma and COPD were
signiﬁcantly associated with the OCS use (p < 0.0001). The
percentage of patients aged 65 years old or more was the
strongest predictor of OCS prescriptions (p < 0.0001). Practices in
the highest quintile prescribed 1.74 times more OCS (IRR= 1.74;
95% CI: 1.64–1.84) than those in the lowest one. Practise list size
was also a positive predictor of OCS prescribing (p < 0.0001) and
the most deprived areas were less likely to prescribe less OCS than
the least deprived areas (IRR= 0.84; 95% CI: 0.80–0.88).
OCS were associated with BP prescriptions (p < 0.0001), with
higher OCS prescribing rates to have been associated with higher
BP prescribing rates (5th to 1st quintile—IRR= 1.99; 95% CI:
Table 1. Characteristics of practices included in the analysis (from
January 2018 to December 2018).
Median IQR
Asthma prevalence (%) 6.0 5.1–6.8
COPD prevalence (%) 1.8 1.3–2.5
Practice list size 7478 4664–11,270
Patients with long-term health conditions (%) 51.7 45.5–59.1
Patients over 65 years old (%) 17.4 12.2–21.8
Quality Outcomes Framework score 549.0 534.7–556.8
OCS prescribed items per 1000 patients 120.8 84.8–160.4
BP prescribed items per 1000 patients 107.7 73.8–147.4
COPD chronic obstructive pulmonary disease, OCS oral corticosteroids, BP
bisphosphonates.
Fig. 1 Long-term prescribing patterns. Total (a) oral corticosteroids (OCS) and (b) bisphosphonates (BP) prescribed items per 1000
population over the period from 1998 to 2018. The arrows provide factors that may have affected their prescribing.
Table 2. Trends in ratio between oral corticosteroids and
bisphosphonates over the period of 2015−2018.
Year OCS items BP items Ratio scale (OCS/BP)
2015 7,781,584 7,836,568 0.99
2016 7,958,014 7,479,733 1.06
2017 7,911,005 7,062,931 1.12
2018 7,799,798 6,728,997 1.16
OCS oral corticosteroids, BP bisphosphonates.
CV Chalitsios et al.
2
npj Primary Care Respiratory Medicine (2020)     5 Published in partnership with Primary Care Respiratory Society UK
1
2
3
4
5
6
7
8
9
0
()
:,;
1.88–2.10) (Table 4). COPD was signiﬁcantly associated with a BP
prescription (p < 0.0001), but asthma was not (p= 0.6848).
Practices located in more deprived areas were 28% less likely to
prescribe less BP than the least deprived practices (IRR= 0.72; 95%
CI: 0.68–0.77).
The CCG to which a practice belongs was signiﬁcantly
associated with prescribing rates and accounted for 11% and
5% of the variation in OCS and BP prescribing, respectively.
We also found similar results in the other years (Supplementary
Tables 4–12).
DISCUSSION
Overall, we observed an increase in prescribed OCS and BP items
between 1998 and 2018. We found large variation in prescribing
rates across practices in England. Asthma and COPD were
signiﬁcantly related with OCS prescriptions, but only COPD with
BP. Patient list size, deprivation and advanced age were all
associated with both the drugs. The CCG to which each practice
belongs also contributed to the prescribing variation. Finally, OCS
was positively associated with BP prescriptions.
The increase in BP prescriptions (2000–2010) could be
explained by the uptake of clinical guidance. The FDA approved
alendronate use in June 199920; the ﬁrst guidance for the GIOP
prevention from the American College of Rheumatology was
published in 200121 and NICE recommended BP as ﬁrst-line GIOP
prophylaxis in 2005.22 The plateauing of BP prescriptions from
2010 with a downward trend from 2015, in contrast with the
steady OCS prescriptions, may reﬂect the FDA concerns23,24 about
BP side effects such as osteonecrosis of the jaw and atypical
femoral fractures. In 2014, the release of the second report of
American Society of Bone and Mineral Research provided a more
robust evidence about the atypical fractures as BP side effects
probably was the reason for a further decrease.25 An investigation
in the USA found a similar 50% reduction in BP use between 2008
and 2012 following concerns about their safety.26 However, these
side effects might be greater concern in younger age groups, as
they will beneﬁt less using BP. Our ﬁndings are also consistent
with two other studies that found a steady increase in BP use from
2000 onwards.27,28
Establishing an optimal ratio of BP to OCS prescription is
challenging. Τhe management of multi-morbidities makes pre-
scribing decisions complex and although prescriptions should be
guideline informed, they should not be guideline directed.29,30
Initiation of BP medication may also depend on how long past
3 months OCS exposure is expected. There is good evidence that
the beneﬁts of BP in preventing GIOP outweigh the risks25,31,32
and bone mineral density testing is recommended within
6 months after OCS initiation, repeating it every 1–3 years.33
Other potential options for GIOP may be recommended (Vitamin
D, HRT), but have less data.
Our analysis demonstrates geographical variation across
practices and CCGs in prescribing rates of both classes of drugs
and in between the drugs. Apart from variation associated with
practice factors, our results revealed that CCGs accounted for
variation in each medication that may indicate differences in
prescribing policy. Interestingly, prescribing differences related to
deprivation, in terms of OCS, may reﬂect inequity of access to
treatment difference, whereas in BP rates, may reﬂect access to
DEXA scanning. Our ﬁndings are consistent with another UK study
that found marked regional differences in the anti-osteoporosis
prescribing rates.26 Other studies have also conﬁrmed the impact
of deprivation and the other examined factors on variation in drug
prescribing.34–36
Despite the proven beneﬁts of BP as an osteoporosis therapy,
there is evidence that they are underutilised both in the UK and
Fig. 2 Geographical variation in prescribing. Geographical variations in (a) oral corticosteroids (OCS) and (b) bisphosphonates (BP)
prescribed items categorised into quantiles among Clinical Commissioning Groups from January to December 2018.
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USA.19,28 Addressing this issue will hinge on education in both
primary and secondary care, and provision of suitable guide-
lines. One practical solution in healthcare systems that use
electronic records/prescribing would be to ﬂag patients who
meet BP criteria based on age, gender and OCS use. Alerts
already occur for a number of conditions (including excess
salbutamol use) and this ﬂag could be incorporated into the
chronic disease review.
Although there is clear guidance on OCS and BP therapy, there
is no current recommendation for BP therapy for inhaled
corticosteroid (ICS) users, despite evidence supporting an
increased osteoporotic fracture risk related to ICS.37–39 It is best
practice to review ICS dose and use the lowest dose possible to
maintain asthma control.40
We also found that the rise in OCS cost was mainly driven by a
steep increase in price of hydrocortisone tablets from 2008
onwards; and BP prescribing went up as BP cost went down
after 2005.
To our knowledge, this is the ﬁrst study to examine the OCS and
BP prescribing patterns and their association with practice-level
factors. We use real prospectively collected prescribing data based
on NHS Digital ﬁles and included practices and CCGs covering the
entire country. There are some limitations; we could not evaluate
prescriptions in secondary care. Secondly, we were not able to
Table 3. Oral corticosteroids prescribing rates in 2018, stratiﬁed by seven practice characteristics and two respiratory diseases in a negative binomial
model reporting incidence rate ratio.
Quintile range Median OCS prescription
per 1000 patients
Univariate model
IRR (95% CI)a
Multivariate model
IRR (95% CI)b
p valuec
Asthma prevalence (%) ≤4.85 69.26 Reference Reference <0.0001
4.86–5.67 109.48 1.46 (1.39–1.51) 1.11 (1.08–1.15)
5.68–6.29 128.56 1.69 (1.61–1.76) 1.18 (1.13–1.23)
6.30–6.98 144.31 1.90 (1.82–1.98) 1.23 (1.18–1.29)
6.99–12.56 157.61 2.10 (2.01–2.19) 1.28 (1.22–1.34)
COPD prevalence (%) ≤1.17 69.68 Reference Reference <0.0001
1.18–1.65 107.95 1.48 (1.42–1.55) 1.13 (1.09–1.17)
1.66–2.10 128.56 1.77 (1.70–1.85) 1.20 (1.15–1.25)
2.11–2.69 144.67 1.95 (1.87–2.04) 1.26 (1.21–1.33)
2.70–10.45 155.17 2.10 (2.01–2.20) 1.34 (1.27–1.41)
Practice list size ≤4,127 112.14 Reference Reference <0.0001
4128–6287 120.98 1.03 (0.98–1.08) 1.01 (0.97–1.05)
6290–8809 127.64 1.04 (0.99–1.09) 1.00 (0.97–1.05)
8810–12,335 129.77 1.05 (1.01–1.10) 0.98 (0.95–1.02)
≥12,336 118.48 0.91 (0.86–0.95) 0.88 (0.85–0.91)
QOF score ≤529.81 111.24 Reference Reference 0.2579
529.82–545.04 115.02 1.05 (1.01–1.11) 1.03 (0.99–1.07)
545.05–552.16 118.01 1.08 (1.03–1.13) 1.02 (0.99–1.06)
552.17–557.84 128.73 1.15 (1.10–1.21) 1.01 (0.98–1.06)
557.85–559 137.49 1.24 (1.18–1.30) 1.02 (0.98–1.07)
% over 65 years old ≤11.00 68.16 Reference Reference <0.0001
11.01–15.63 106.01 1.50 (1.44–1.56) 1.24 (1.20–1.28)
15.64–18.86 126.68 1.78 (1.70–1.85) 1.39 (1.34–1.46)
18.87–22.77 139.56 1.95 (1.87–2.04) 1.49 (1.42–1.57)
≥22.78 172.23 2.40 (2.30–2.50) 1.74 (1.64–1.84)
% patients with a long-term
health disease
≤43.95 73.53 Reference Reference 0.1923
43.97–49.65 109.62 1.40 (1.34–1.47) 1.03 (0.99–1.06)
49.66–53.85 128.86 1.64 (1.56–1.71) 1.04 (1.01–1.08)
53.86–58.44 140.36 1.77 (1.69–1.85) 1.03 (0.99–1.07)
≥58.45 151.76 1.91 (1.83–2.00) 1.04 (0.99–1.08)
IMD score Least deprived 126.98 Reference Reference <0.0001
— 134.29 1.03 (0.98–1.08) 0.92 (0.88–0.95)
— 122.00 0.96 (0.91–1.01) 0.87 (0.83–0.90)
— 115.85 0.89 (0.85–0.94) 0.85 (0.81–0.88)
Most deprived 110.01 0.88 (0.84–0.92) 0.84 (0.80–0.88)
OCS oral corticosteroids, COPD chronic obstructive pulmonary disease, QOF Quality and Outcomes Framework, IMD Index of Multiple Deprivation.
aNegative binomial model.
bMixed-effects negative binomial model.
cFrom multivariate analysis using the likelihood ratio test.
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know the indication for each prescription. Thirdly, we could not
perform individual-level analysis in order to identify the OCS
prescriptions that need BP therapy according to the guidelines’
recommendations.
In conclusion, the overall levels of OCS and BP prescription
have increased since 1998. Concerns about BP adverse effects
may account for a latter reduction in BP prescriptions in contrast
to steady or increased OCS prescriptions. We found clear
variation in OCS and BP, and this unwarranted variation appears
to be driven to a large extent by factors including deprivation,
patient list size and CCGs. The variation in prescribing suggests
there is still a need to improve GIOP prevention.
Table 4. Bisphosphonates prescribing rates in 2018, stratiﬁed by seven practice factors and OCS per 1000 patients in a negative binomial model
reporting incidence rate ratio.
Quintile range Median BP prescription
per 1000 patients
Univariate model
IRR (95% CI)a
Multivariate model
IRR (95% CI)b
p valuec
Asthma prevalence (%) ≤4.85 72.87 Reference Reference 0.6848
4.86–5.67 100.36 1.23 (1.21–1.33) 1.01 (0.96–1.04)
5.68–6.29 115.37 1.44 (1.38–1.52) 1.04 (0.99–1.08)
6.30–6.98 121.57 1.55 (1.47–1.63) 1.01 (0.96–1.05)
6.99–12.56 128.56 1.67 (1.59–1.76) 1.01 (0.97–1.07)
COPD prevalence (%) ≤1.17 67.37 Reference Reference <0.0001
1.18–1.65 98.71 1.40 (1.37–1.47) 1.08 (1.04–1.12)
1.66–2.10 115.18 1.63 (1.56–1.72) 1.13 (1.08–1.19)
2.11–2.69 123.80 1.72 (1.64–1.80) 1.15 (1.09–1.21)
2.70–10.45 131.90 1.85 (1.76–1.94) 1.19 (1.12–1.26)
OCS per 1000 patients ≤75.37 52.66 Reference Reference <0.0001
75.40–108.44 89.60 1.63 (1.56–1.70) 1.39 (1.34–1.46)
108.56–136.24 110.94 2.00 (1.91–2.09) 1.58 (1.51–1.66)
136.27–169.84 128.78 2.32 (2.22–2.43) 1.74 (1.66–1.83)
≥169.85 161.98 2.94 (2.82–3.07) 1.99 (1.88–2.10)
Practice list size ≤4127 102.46 Reference Reference <0.0001
4128–6287 110.85 1.03 (0.98–1.09) 0.99 (0.96–1.03)
6290–8809 113.50 1.04 (0.98–1.08) 0.97 (0.93–1.01)
8810–12,335 112.61 1.04 (0.98–1.09) 0.97 (0.90–0.97)
≥12,336 104.82 0.90 (0.85–0.95) 0.96 (0.90–0.91)
QOF score ≤529.81 97.30 Reference Reference <0.0001
529.82–545.04 102.15 1.04 (0.99–1.10) 1.05 (1.01–1.09)
545.05–552.16 106.40 1.08 (1.03–1.14) 1.07 (1.03–1.11)
552.17–557.84 115.61 1.16 (1.10–1.23) 1.07 (1.03–1.11)
557.85–559 123.05 1.25 (1.19–1.32) 1.09 (1.04–1.13)
% over 65 years old ≤11 54.77 Reference Reference <0.0001
11.01–15.63 95.43 1.63 (1.56–1.71) 1.35 (1.29–1.40)
15.64–18.86 112.63 1.98 (1.89–2.07) 1.50 (1.42–1.58)
18.87–22.77 127.56 2.20 (2.10–2.30) 1.59 (1.50–1.68)
≥22.78 154.39 2.66 (2.54–2.78) 1.82 (1.71–1.94)
% patients with a long-term
health disease
≤43.95 70.30 Reference Reference 0.3457
43.97–49.65 98.73 1.36 (1.30–1.43) 1.03 (0.99–1.08)
49.66–53.85 116.34 1.56 (1.49–1.64) 1.03 (0.98–1.08)
53.86–58.44 123.56 1.66 (1.59–1.75) 1.01 (0.96–1.05)
≥58.45 131.17 1.82 (1.73–1.91) 1.04 (0.99–1.09)
IMD score Least deprived 117.83 Reference Reference <0.0001
— 122.89 1.03 (0.97–1.18) 0.93 (0.90–0.97)
— 111.17 0.92 (0.87–0.96) 0.85 (0.82–0.90)
— 102.84 0.84 (0.81–0.88) 0.80 (0.76–0.84)
Most deprived 85.29 0.74 (0.70–0.78) 0.72 (0.68–0.77)
BP bisphosphonates, COPD chronic obstructive pulmonary disease, OCS oral corticosteroids, QOF Quality and Outcomes Framework, IMD Index of Multiple
Deprivation.
aNegative binomial model.
bMixed-effects negative binomial model.
cFrom multivariate analysis using the likelihood ratio test.
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METHODS
Data sources
We used national data based on the annual prescription cost analysis (PCA)
from 1998 to 2018, and monthly practice-level data ﬁles by NHS Digital
from January 2015 to December 2018.
The annual prescription cost analysis data ﬁles provide details of the
number of items and net ingredient cost of all prescriptions for each
medication dispensed in the community in England. Data were normalised
by converting to relative ﬁgures per 1000 population using mid-year
population estimate for England.41 The monthly data published by NHS
Digital consist of one row for each medication providing information about
the prescribing volume and cost for each practice in England. These data
are based on claims from community pharmacies and contains items that
have been dispensed.
We extracted the data from OpenPrescribing (https://openprescribing.
net/) database. OpenPrescribing is built by EBM Data Lab and provides a
search interface onto the raw prescribing data ﬁles published by NHS,
making the access to this complex information easier in order for these
data to be more impactful in real world. There are approximately 900
million rows of these data. New data are released every month; however,
they are 2 months behind (i.e. March’s prescribing data are published in
May). OpenPrescribing has data from the past 5 years without containing
any patient information and indication of the treatment length.
Study design
We conducted a retrospective cohort with ecological elements study on all
English practices and CCGs, measuring patterns in OCS and BP prescribing
items over time at practice level. We described the ratio in prescribing rate
between OCS and BP and measured any variation among CCGs
geographically. We also matched the monthly practice-level data with
open access data derived from Public Health England to investigate for
reason for any variation in OCS and BP prescribing at practice and
CCG level.
Drugs extraction
We used prescribed “items” as a measure of prescribing. A prescription
item refers to a single supply of a medicine prescribed on a prescription
form. If a prescription form includes three medicines, it is counted as three
prescription items.
We extracted prescribing and cost data for the following OCS as are
stated on OpenPrescribing.net: Beclometasone Dipropionate (Systemic)
(Brand name: Clipper), Budesonide (Brand names: Entocort, Budenofalk)
derived from section “1.2.5: Corticosteroids” of the British National
Formulary (BNF) book. Betamethasone Sodium Phosphate (brand names:
Betnesol, Betameth sod phos, all systemic), Cortisone Acetate (brand name:
Cortisone acet), Deﬂazacort (brand name: Calcort), Dexamethasone (brand
name: Dexameth (systemic)), Hydrocortisone (brand name: Hydrocortone,
Hydrocort (systemic)), Methylprednisolone (brand name: Medrone (sys-
temic)), Prednisolone (brand name: Prednisolone (systemic)), and Pre-
dnisone (brand name: Lodotra) were derived from section “6.3.2:
Glucocorticoid therapy” of the BNF (Supplementary Table 2).
We extracted data about bisphosphonates following guidance from the
National Osteoporosis Guideline Group.12 These were: Alendronic acid
(brand names: Alendronic acid, Fosamax), risedronate sodium (brand
names: Actonel, Risedronate sod) and Zoledronic acid (brand name:
Zometa). All BP were checked against section “6.6.2: Bisphosphonates and
other drugs” of the BNF (Supplementary Table 1).
Long-term patterns
Data from OpenPrescribing.net based on PCA were obtained describing
the annual patterns in OCS and BP prescribing items and cost per 1000
population from 1998 to 2018. We aggregated the total annual items/cost
per 1000 population of each OCS/BP type. We created stacked graphs to
depict the annual volume of each chemical of each drug per 1000
population.
Ratio between OCS and BP prescriptions
We extracted monthly data about OCS and BP prescribed items per CCG
from January 2015 to December 2018. We aggregated the monthly items
of each CCG per year obtaining the total annual number of both OCS and
BP items. The ratio between the above classes of drugs was calculated
using:
Ratio ¼ Total OCS items the year of interest
Total BP items the year of interest
 
:
Variations among CCGs for OCS and BP items
In 2012, each practice was grouped into CCGs. The CCGs are responsible
for the planning and commissioning of healthcare in a local community. To
examine geographical variations in OCS and BP prescribing in 2018,
practices were grouped by CCG. The prescribing rate per 1000 patients of
dispensed OCS/BP for each CCG was derived by dividing the total number
of prescribing items by the mean patient list size over the year in each
CCG, multiplied by 1000. Then, they were categorised into quantiles.
Associations between OCS and BP prescribing
After calculating the rate of OCS and BP items per 1000 patients per
practice, we determined other independent variables to examine which
indicators were associated with OCS and BP prescription in 2018. We
repeated the analysis for 2015, 2016 and 2017.
Data were extracted on the following factors from the Public Health
England (https://ﬁngertips.phe.org.uk/proﬁle/general-practice/data): the
percentage of (a) asthma diagnosis, (b) COPD diagnosis, (c) patients over
65 years old, (d) patients with a long-term health condition deﬁned as the
percentage of people who answered “Yes” in the practices’ patient survey
(http://www.gp-patient.co.uk/practices-search) question: “Do you have any
long-term physical or mental health conditions, disabilities or illnesses?”,
(e) the Index of Multiple Deprivation (IMD) score, and (f) the mean practice
list size.
All of the above ﬁgures were derived from the correspondence year of
interest apart from the IMD score which was available only for 2015; we
used this score for the analysis in each year of interest. All of the above
indicators were obtainable based on the CCGs which were active in 2017/
2018. Furthermore, we extracted data about the Quality and Outcomes
Framework Score (QOF) score (https://digital.nhs.uk/data-and-information/
publications/statistical/quality-and-outcomes-framework-achievement-
prevalence-and-exceptions-data) by practice. We used the 2017/2018 QOF
score not only in the analysis for the year 2017 but also in 2018 as the
2018/2019 QOF score had not been released yet. Additionally, we excluded
practices without a QOF or having a list size less than 1000 patients
(Supplementary information, Practice exclusion).
Statistical methods
Practices’ characteristics as well as OCS and BP prescriptions were analysed
using descriptive analysis reporting them as median along with IQR. A
paired t test was performed examining the signiﬁcance of variation
between OCS and BP prescription among CCGs. To examine the
association between OCS/BP per 1000 patients and the factors, we
conducted a negative binomial regression analysis. We stratiﬁed the rate of
OCS and BP prescribing for each one of the investigating factors. We put
these factors in the model. We also split the OCS per 1000 patients into
quintiles and put them in the BP analysis. Afterwards, as healthcare policies
and commissioning differ among CCGs, we used a mixed-effect negative
binomial model, deﬁning the rate of OCS and BP prescriptions per 1000
patients as the dependent variable. We used the factors deﬁned above as
ﬁxed-effects explanatory variables, and the CCG of each practice as a
random-effect variable. The variables were grouped into quintiles to allow
for nonlinearity of effects. IRRs with a 95% CI were used to determine the
strength of associations and R2 to show the value and signiﬁcance of
variance associated with CCG grouping. P values < 0.05 were considered
statistically signiﬁcant. Practices with missing values were less than 0.25%.
Python was used for data management. Both graphs and maps were
constructed with Python. Statistical analysis was conducted by using Stata,
version 16.
Reporting summary
Further information on experimental design is available in the Nature
Research Reporting Summary linked to this article.
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